Skip to main content

Wiley Matthew T.

In the past year, 1 open-market sale filing worth $129.1K and no purchases.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
$129.1K
1 filing
Net
−$129.1K
Bought minus sold
Companies
1
With open-market trades

Trades

Every Form 4 that lists Wiley Matthew T. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

DFTX Definium Therapeutics, Inc.

Chief Commercial Officer1 trade

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 26, 2026 (view filing)Jun 251 dayWiley Matthew T.Chief Commercial OfficerSSale−2.87K$45.03−$129.1K−1.6%174.6K after10b5-1

BTAIQ BioXcel Therapeutics, Inc.

Other: See Remarks4 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 3, 2024 (view filing)Oct 3Same dayWiley Matthew T.Chief Commercial OfficerSSale−6.27K$0.55−$3.45K−24.8%19.0K after10b5-1
Sep 17, 2024 (view filing)Sep 161 dayWiley Matthew T.Chief Commercial OfficerSSale−215$0.69−$148.35−5.1%4.03K after10b5-1
Jun 18, 2024 (view filing)Jun 171 dayWiley Matthew T.Chief Commercial OfficerSSale−244$1.26−$307.44−6.5%3.50K afterFrom original
Apr 8, 2024 (view filing)Apr 44 daysWiley Matthew T.CHIEF COMMERCIAL OFFICERSSale−1.01K$2.64−$2.66K−25.2%2.99K after10b5-1